Antitumorigenic Effect of Combination Treatment with BRAF Inhibitor and Cisplatin in Colorectal Cancer In Vitro and In Vivo
Open Access
- 16 November 2024
- journal article
- research article
- Published by Wiley in Advanced Therapeutics
- Vol. 8 (1)
Abstract
In colorectal cancer (CRC), BRAF inhibitor (BRAFi) monotherapy appears ineffective, while cisplatin treatment is associated with adverse effects, drug resistance, and reduced efficacy. Herein, a combinatorial approach is being explored to increase the likelihood of effectively killing colorectal cancer cells. The combined effect of BRAFi (PLX4720, Vemurafenib, Dabrafenib, Encorafenib) and cisplatin treatment is examined in BRAFV600E‐mutated (RKO, HT29, Colo‐205) and BRAFwt (Caco‐2) cell lines, as well as in mouse xenografts of RKO cells. Following cisplatin‐only treatment, all cell lines show accumulation within subG1 (apoptotic cells) and G2/M phases, as well as phosphorylation of ERK1/2 and H2AX. Following BRAFi‐only treatment, BRAFV600E‐mutated cells show accumulation within G0/G1 phase, reduced distribution in the S and G2/M phases, inhibition of ERK1/2 phosphorylation, and increased phosphorylation of H2AX. Combined BRAFi and cisplatin treatment synergistically decrease RKO cells viability, reduce phosphorylation of ERK1/2, and increase phosphorylation of H2AX. Importantly, in mouse xenografts of RKO cells, combined PLX4720 and cisplatin treatment show superior therapeutic potential than each monotherapy (P < 0.001). Taken together, in in vitro and in vivo preclinical models, BRAFi and cisplatin combined treatment has shown an improved antitumor effect, rendering it a potential anticancer treatment strategy for BRAF‐mutant colon cancer patients.Keywords
All Related Versions
Funding Information
- Ministry of Education and Religious Affairs, Sport and Culture (MIS5002398)
This publication has 53 references indexed in Scilit:
- BRAF paradox breakers PLX8394, PLX7904 are more effective against BRAFV600Ε CRC cells compared with the BRAF inhibitor PLX4720 and shown by detailed pathway analysisBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2021
- RAS/MAPK signaling functions in oxidative stress, DNA damage response and cancer progressionJournal of Cellular Physiology, 2019
- SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer (2018)Clinical and Translational Oncology, 2018
- Clinical Pharmacokinetics and Pharmacodynamics of DabrafenibClinical Pharmacokinetics, 2018
- Encorafenib (LGX818), a potent BRAF inhibitor, induces senescence accompanied by autophagy in BRAFV600E melanoma cellsCancer Letters, 2016
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012International Journal of Cancer, 2014
- Phase 1 study of sorafenib in combination with bortezomib in patients with advanced malignanciesInvestigational New Drugs, 2013
- A Landscape of Driver Mutations in MelanomaCell, 2012
- Inheritance of colorectal cancerDrug Discovery Today: Disease Mechanisms, 2007
- Continuous ERK Activation Downregulates Antiproliferative Genes throughout G1 Phase to Allow Cell-Cycle ProgressionCurrent Biology, 2006